Streetbeat News

PHRRF

PharmaTher Holdings Ltd

Industry

Pharmaceutical Preparation Manufacturing

Open

0.17

Mkt cap

15M

Volume

50K

High

0.17

P/E Ratio

-4.20

52-wk high

0.32

Low

0.17

Div yield

N/A

52-wk low

0.09

PharmaTher Holdings has partnered with Vitruvias Therapeutics for the commercialization of its proprietary racemic ketamine products, KETARX, in the U.S. market. PharmaTher will be responsible for regulatory, manufacturing, and supply, while Vitruvias will handle marketing, sales, and distribution. PharmaTher plans to file its Abbreviated New Drug Application (ANDA) for KETARX with the FDA in early July and expects approval in Q1 2024.

Portfolio Pulse from Lara Goldstein

June 21, 2023 | 2:38 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.